August 14, 2025
SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update
First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical hold, triggering a $10M…
Pharmaceuticals, Biotechnology and Life Sciences
First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical hold, triggering a $10M…
– Positive 12-month Phase 1/2 clinical data in adult cohort and early pediatric clinical data support potential for meaningful vision…
Tuspetinib Continues to Demonstrate Excellent Safety and Complete Responses in the TUSCANY Clinical Trial of Tuspetinib in AML Triple Drug…
Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical study of NPM-139…
Strong performance driven by over 200% growth in product revenues year-on-year Best quarter in Alvotech’s history in terms of operating…
Strong performance driven by over 200% growth in product revenues year-on-year Best quarter in Alvotech’s history in terms of operating…
A now resolved supply disruption led to Q2 net product revenue decline but higher profitability due to increased usage of…
Compelling new ARD-201 preclinical data informs optimized Phase 2 clinical development strategy of obesity programs: Phase 2 POWER trial of…
REDWOOD CITY, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company…
Presented preclinical data for JADE101 at the 62nd European Renal Association Congress, highlighting its potential as a best-in-class anti-APRIL monoclonal…